Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice

Hypertension

Volumn 54, Issue 5, 2009, Pages 1129-1135

  Suzuki, Hirotada ^a   Ohkuchi, Akihide ^a   Matsubara, Shigeki ^a   Takei, Yuji ^a   Murakami, Masato ^b   Shibuya, Masabumi ^b   Suzuki, Mitsuaki ^a   Sato, Yasufumi ^c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Adenoviral vector; Animal models; Placental growth factor; Preeclampsia; Soluble fms like tyrosine kinase 1; Therapy; Vascular endothelial growth factor

Indexed keywords

ADENOVIRUS VECTOR; FMS RELATED TYROSINE KINASE 1; LYMPHOCYTE ANTIGEN; PLACENTAL GROWTH FACTOR; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MEMBRANE PROTEIN; PIGF PROTEIN, HUMAN; PLACENTA PROTEIN; PRODUCT PLACENTA GROWTH FACTOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HYPERTENSION; MOUSE; NONHUMAN; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; ADENOVIRUS; ANIMAL; BREEDING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; GENE VECTOR; GENETICS; HUMAN; MOUSE STRAIN; PROBABILITY; RANDOMIZATION; REFERENCE VALUE;

ADENOVIRIDAE; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; HUMANS; HYPERTENSION; MEMBRANE PROTEINS; MICE; MICE, INBRED STRAINS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY, ANIMAL; PROBABILITY; PROTEINURIA; RANDOM ALLOCATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; REFERENCE VALUES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70449726966     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.134668     Document Type: Article

References (39)

1. Nagaya K, Fetters MD, Ishikawa M, Kubo T, Koyanagi T, Saito Y, Sameshima H, Sugimoto M, Takagi K, Chiba Y, Honda H, Mukubo M, Kawamura M, Satoh S, Neki R. Causes of maternal mortality in Japan. JAMA. 2000;283:2661-2667.
2. Hecher K, Campbell S, Doyle P, Harrington K, Nicolaides K. Assessment of fetal compromise by Doppler ultrasound investigation of the fetal circulation: arterial, intracardiac, and venous blood flow velocity studies. Circulation. 1995;91:129-138.
3. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and pro-teinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
4. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683.
5. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; for the CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005.
6. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21:60-65.
7. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278:12605-12608.
8. Bridges JP, Gilbert JS, Colson D, Gilbert SA, Dukes MP, Ryan MJ, Granger JP. Oxidative stress contributes to soluble Fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens. 2009;22:564-568.
9. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993;90:10705-10709.
10. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones DS. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod. 1998;59:1540-1548.
11. Yamaguchi S, Iwata K, Shibuya M. Soluble Flt-1 (soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem Biophys Res Commun. 2002;291:554-559.
12. Chen H, Ikeda U, Shimpo M, Maeda Y, Shibuya M, Ozawa K, Shimada K. Inhibition of vascular endothelial growth factor activity by transfection with the soluble FLT-1 gene. J Cardiovasc Pharmacol. 2000;36: 498-502.
13. Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marmé D, Martiny-Baron G. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endo-thelial growth factor FLT-1. J Biol Chem. 1997;272:10382-10388.
14. Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitarai K, Shibuya M. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem. 1998;273:31283-31288.
15. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E, D'Amato R, Folkman J, Mulligan RC. Comparative evaluation of the antitumor activity of anti-angiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A. 2001;98:4605-4610.
16. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642-649. (Pubitemid 43865232)
17. Lu F, Bytautiene E, Tamayo E, Gamble P, Anderson GD, Hankins GD, Longo M, Saade GR. Gender-specific effect of overexpression of sFlt-1 in pregnant mice on fetal programming of blood pressure in the offspring later in life. Am J Obstet Gynecol. 2007;197:418.e1-e5.
18. Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson GD, Hankins GD, Saade GR. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol. 2007;196: 396.e1-e7.
19. Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension. 2007;50:686-692.
20. Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Gonçalves LF, Medina L, Edwin S, Hassan S, Carstens M, Gonzalez R. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol. 2007;196:326.e1-326.e13.
21. Ohkuchi A, Hirashiama C, Matsubara S, Suziki H, Takahashi K, Arai F, Watanabe T, Kario K, Suzuki M. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res. 2007;30:151-159.
22. Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy. 2004;23:101-111.
23. Kondo K, Hiratsuka S, Subbalakshmi E, Matsushime H, Shibuya M. Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship betweet the 7-Ig and the 5-Ig tyrosine kinase receptor. Gene. 1998;208:297-305.
24. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, Ohta H, Imagawa K, Hojo K, Maki H, Sonoda H, Sato Y. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest. 2004;114:898-907.
25. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM. VEGF-dependent plasticity of fenestrated capillaries in the normal adult micro-vasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560-H576.
26. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
27. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, flu-orouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med. 2004;350:2335-2342.
28. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chebreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; for the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Eng J Med. 2007;356:125-134.
29. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011-2019. (Pubitemid 350236338)
30. Li B, Ogasawara AK, Yang R, Wei W, He GW, Zioncheck TF, Buntinq S, de Vos AM, Jin H. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension. 2002;39:1095-1100.
31. Yang R, Ogasawara AK, Zioncheck TF, Ren Z, He GW, DeGuzman GG, Pelletier N, Shen BQ, Bunting S, Jim H. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension. 2002;39:815-820.
32. Parsons-Wingerter P, Chandrasekharan UM, McKay TL, Radhakrishnan K, DiCorleto PE, Albarran B, Farr AG. A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity. Microvasc Res. 2006;72:91-100.
33. Sandrim VC, Palei AC, Metzger IF, Gomes VA, Cavalli RC, Tanus-Santos JE. Nitric oxide formation is inversely related to serum levels of antian-giogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension. 2008;52:402-407.
34. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol. 1994;171: 818-822.
35. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor: potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem. 1994;269:25646-25654.
36. Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ. 1996;7:213-221. (Pubitemid 26049830)
37. Osol G, Celia G, Gokina N, Barron C, Chien E, Mandala M, Luksha L, Kublickiene K. Placental growth factor is a potent vasodilator of rat and human resistance arteries. Am J Physiol Heart Circ Physiol. 2008;294: H1381-H1387.
38. Abid MR, Schoots IG, Spokes KC, Wu SQ, Mawhinney C, Aird WC. Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and IkappaB/NF-kappaB. J Biol Chem. 2004;279:44030-44038.
39. González-Pacheco FR, Deudero JJ, Castellanos MC, Castilla MA, Alvarez-Arroyo MV, Yagüe S, Caramelo C. Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. Am J Physiol Heart Circ Physiol. 2006;291:H1395-H1401